Clarivate Epidemiology’s coverage of myasthenia gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and the diagnosed incidence of myasthenia gravis for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report.
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology’s myasthenia gravis forecast will answer the following questions:
In addition to the total number of cases for each forecast year, Clarivate Epidemiology also provides at least ten years of forecast data for the following myasthenia gravis subpopulations:
Note: Coverage may vary by country.